Breaking News

Imprimis Registers Texas Site as an Outsourcing Facility

Planned outsourcing facility is expected to comply with cGMP

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Imprimis Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, started construction on the company’s Allen, TX, compounding pharmacy and plans to register the pharmacy with the U.S. Food and Drug Administration (FDA) as a 503B sterile outsourcing facility under the Drug Quality and Security Act (DQSA) of 2013. The DQSA was signed into law by President Obama on November 27, 2013 and created a new p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters